Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
APLM logo APLM
Upturn stock ratingUpturn stock rating
APLM logo

Apollomics Inc. Class A Ordinary Shares (APLM)

Upturn stock ratingUpturn stock rating
$9.29
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: APLM (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $2

1 Year Target Price $2

Analysts Price Target For last 52 week
$2 Target price
52w Low $3.66
Current$9.29
52w High $19.4

Analysis of Past Performance

Type Stock
Historic Profit -25.83%
Avg. Invested days 11
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.64M USD
Price to earnings Ratio -
1Y Target Price 2
Price to earnings Ratio -
1Y Target Price 2
Volume (30-day avg) 1
Beta 0.89
52 Weeks Range 3.66 - 19.40
Updated Date 09/15/2025
52 Weeks Range 3.66 - 19.40
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -52.8

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) 1007.39%

Management Effectiveness

Return on Assets (TTM) -75.07%
Return on Equity (TTM) -233.67%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5839066
Price to Sales(TTM) 73.93
Enterprise Value 5839066
Price to Sales(TTM) 73.93
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.1
Shares Outstanding 2143350
Shares Floating 934348
Shares Outstanding 2143350
Shares Floating 934348
Percent Insiders -
Percent Institutions 0.67

ai summary icon Upturn AI SWOT

Apollomics Inc. Class A Ordinary Shares

stock logo

Company Overview

overview logo History and Background

Apollomics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of immuno-oncology and targeted therapies to treat multiple cancers. Founded in 2015, it aims to address unmet medical needs in oncology by bringing innovative and effective therapies to patients globally.

business area logo Core Business Areas

  • Drug Development: Focuses on the discovery and development of novel oncology therapeutics, including immuno-oncology and targeted therapies.
  • Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in cancer patients.
  • Commercialization: Aims to commercialize its approved drugs globally, primarily through partnerships and strategic alliances.

leadership logo Leadership and Structure

Apollomics is led by a team of experienced pharmaceutical executives and scientists. The company has a board of directors overseeing its strategic direction. The organizational structure includes research and development, clinical operations, commercial planning, and finance departments.

Top Products and Market Share

overview logo Key Offerings

  • APL-101: A targeted therapy being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors. Currently in clinical trials. Market share data is not yet applicable as the drug is not yet approved. Competitors include pharmaceutical companies with marketed NSCLC therapies, such as AstraZeneca (AZN) and Merck (MRK).
  • APL-106: An immuno-oncology therapy being developed to enhance immune responses against cancer cells. Currently in clinical trials. Market share data is not yet applicable as the drug is not yet approved. Competitors include companies with established immuno-oncology therapies, such as Bristol Myers Squibb (BMY) and Roche (RHHBY).

Market Dynamics

industry overview logo Industry Overview

The oncology market is a rapidly growing segment of the pharmaceutical industry, driven by increasing cancer incidence, aging populations, and advances in drug development. Immuno-oncology and targeted therapies are key growth areas.

Positioning

Apollomics aims to establish itself as a key player in the oncology market through the development and commercialization of innovative therapies. Its competitive advantage lies in its focus on novel targets and its strategic partnerships.

Total Addressable Market (TAM)

The global oncology market is projected to reach hundreds of billions of dollars annually. Apollomics is positioned to capture a portion of this TAM by developing and commercializing innovative cancer therapies.

Upturn SWOT Analysis

Strengths

  • Innovative drug development pipeline
  • Experienced management team
  • Strategic partnerships
  • Focus on high-growth oncology market

Weaknesses

  • Limited commercial infrastructure
  • Dependence on clinical trial success
  • High R&D expenses
  • Significant competition from established pharmaceutical companies

Opportunities

  • Expansion into new therapeutic areas
  • Acquisition of complementary technologies or assets
  • Strategic alliances with larger pharmaceutical companies
  • Accelerated drug development timelines through regulatory pathways

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from existing and emerging therapies
  • Economic downturns impacting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

As a private company, Apollomics faces competition from large pharmaceutical companies and other biotech firms in the oncology space. Its success depends on differentiating its therapies and effectively commercializing them.

Growth Trajectory and Initiatives

Historical Growth: Unavailable due to lack of public financials.

Future Projections: Future growth depends on the success of its clinical trials and commercialization efforts. Analyst estimates are unavailable for a private company.

Recent Initiatives: Recent initiatives include advancing its clinical trial programs for APL-101 and APL-106 and seeking partnerships to expand its pipeline and commercial reach.

Summary

Apollomics is a biopharmaceutical company focused on developing innovative oncology therapies. It is still in the early stages of development with drugs in clinical trials. The company faces significant competition and risks associated with clinical trial success. Its future depends on advancing its pipeline and securing strategic partnerships to commercialize its therapies, but given its private status this analysis cannot be as strong.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • Press Releases
  • Industry Reports

Disclaimers:

This analysis is based on limited publicly available information and is subject to change. Financial data is not available for this private company, leading to a less complete analysis. This is not investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Apollomics Inc. Class A Ordinary Shares

Exchange NASDAQ
Headquaters Foster City, CA, United States
IPO Launch date 2021-11-26
CEO & Chairman of the Board Mr. Hung-Wen Chen
Sector Healthcare
Industry Biotechnology
Full time employees 13
Full time employees 13

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.